Emerging understanding of multiscale tumor heterogeneity

Frontiers in Oncology

Volumn 4, Issue DEC, 2014, Pages

  Gerdes, Michael J ^a   Sood, Anup ^a   Sevinsky, Christopher ^a   Pris, Andrew D ^a   Zavodszky, Maria I ^a   Ginty, Fiona ^a  

^a GE GLOBAL RESEARCH   (United States)

Author keywords

Cancer; Heterogeneity; Multi omic analysis; Multiplexing; Next generation sequencing; Tumor mechanisms; Tumor microenvironment

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CD44V6 ANTIGEN; CYTOKERATIN 5; CYTOKERATIN 7; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MICROTUBULE ASSOCIATED PROTEIN 4; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN P63; PROTEIN S6; THYROID TRANSCRIPTION FACTOR 1; TUMOR MARKER;

ANGIOGENESIS; ANTIGEN EXPRESSION; CANCER STEM CELL; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL SIGNALING ASSAY; CLONAL EVOLUTION; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DNA FRAGMENTATION; EXTRACELLULAR MATRIX; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC HETEROGENEITY; GERMLINE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LUNG CARCINOMA; LUNG ADENOCARCINOMA; METASTASIS; MICROSATELLITE INSTABILITY; NEXT GENERATION SEQUENCING; PROTEIN EXPRESSION; PROTEIN MICROARRAY; REVIEW; SOMATIC MUTATION; SQUAMOUS CELL LUNG CARCINOMA; TH17 CELL; TIME OF FLIGHT MASS SPECTROMETRY; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT;

EID: 84922523746     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00366     Document Type: Review

References (129)

1. Hanahan DW, Weinberg RA. The hallmarks of cancer. Cell (2000) 100:57-70. doi: 10.1016/S0092-8674(00)81683-9
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013
3. Nowell PC. The clonal evolution of tumor cell populations. Science (1976) 194:23-8. doi:10.1126/science.959840
4. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11:726-34. doi:10.1038/nrc3130
5. Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle (2007) 6:2332-8. doi:10.4161/cc.6.19.4914
6. Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res (2008) 14:370-8. doi:10.1158/1078-0432.CCR-07-1127
7. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 366:883-92. doi:10.1056/NEJMoa1113205
8. Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol (2013) 8:277-302. doi:10.1146/annurev-pathol-020712-163923
9. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature (2013) 501:338-45. doi:10.1038/nature12625
10. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res (2006) 66:1883-90. doi:10.1158/0008-5472.CAN-05-3153
11. Shipitsin M, Polyak K. The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest (2008) 88:459-63. doi:10.1038/labinvest.2008.14
12. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med (2011) 17:313-9. doi:10.1038/nm.2304
13. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature (2013) 501:328-37. doi:10.1038/nature12624
14. Gerdes MJ, Yuspa SH. The contribution of epidermal stem cells to skin cancer. Stem Cell Rev (2005) 1:225-31. doi:10.1385/SCR:1:3:225
15. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature (2001) 414:105-11. doi:10.1038/35102167
16. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature (2009) 457:608-11. doi:10.1038/nature07602
17. Powell AE, Vlacich G, Zhao ZY, McKinley ET, Washington MK, Manning HC, et al. Inducible loss of one Apc allele in Lrig1-expressing progenitor cells results in multiple distal colonic tumors with features of familial adenomatous polyposis. Am J Physiol Gastrointest Liver Physiol (2014) 307:G16-23. doi:10.1152/ajpgi.00358.2013
18. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer (2008) 8:755-68. doi:10.1038/nrc2499
19. Li F, Tiede B, Massagué J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res (2007) 17:3-14. doi:10.1038/sj.cr.7310118
20. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 9:265-73. doi:10.1038/nrc2620
21. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res (2010) 16:45-55. doi:10.1158/1078-0432.CCR-09-1630
22. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst (2008) 100:672-9. doi:10.1093/jnci/djn123
23. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 29:4741-51. doi:10.1038/onc.2010.215
24. Abdullah LN, Chow EK. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med (2013) 2:3. doi:10.1186/2001-1326-2-3
25. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 100:3983-8. doi:10.1073/pnas.0530291100
26. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A (2007) 104:10158-63. doi:10.1073/pnas.0703478104
27. Hirsch D, Barker N, McNeil N, Hu Y, Camps J, McKinnon K, et al. LGR5 positivity defines stem-like cells in colorectal cancer. Carcinogenesis (2014) 35:849-58. doi:10.1093/carcin/bgt377
28. Wang Y, Poulin EJ, Coffey RJ. LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor. Br J Cancer (2013) 108:1765-70. doi:10.1038/bjc.2013.138
29. Snippert HJ, Schepers AG, van Es JH, Simons BD, Clevers H. Biased competition between Lgr5 intestinal stem cells driven by oncogenic mutation induces clonal expansion. EMBO Rep (2014) 15:62-9. doi:10.1002/embr.201337799
30. Medema JP. Cancer stem cells: the challenges ahead. Nat Cell Biol (2013) 15:338-44. doi:10.1038/ncb2717
31. Liu Y, Nenutil R, Appleyard MV, Murray K, Boylan M, Thompson AM, et al. Lack of correlation of stem cell markers in breast cancer stem cells. Br J Cancer (2014) 110:2063-71. doi:10.1038/bjc.2014.105
32. de Beça FF, Caetano P, Gerhard R, Alvarenga CA, Gomes M, Paredes J, et al. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. J Clin Pathol (2013) 66:187-91. doi:10.1136/jclinpath-2012-201169
33. Atkinson RL, Yang WT, Rosen DG, Landis MD, Wong H, Lewis MT, et al. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Res (2013) 15:R77. doi:10.1186/bcr3471
34. Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology (2013) 145:554-65. doi:10.1053/j.gastro.2013.05.010
35. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A (2004) 101:811-6. doi:10.1073/pnas.0304146101
36. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 14:5198-208. doi:10.1158/1078-0432.CCR-08-0196
37. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst (2005) 97:1180-4. doi:10.1093/jnci/dji237
38. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature (2000) 406:747-52. doi:10.1038/35021093
39. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med (2009) 360:790-800. doi:10.1056/NEJMra0801289
40. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)? Breast Cancer Version 3.2014. (2014). Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
41. Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, et al. NCCN Task Force Report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw (2009) 7(Suppl 6):S1-21.
42. Rayson D, Richel D, Chia S, Jackisch C, van der Vegt S, Suter T. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Ann Oncol (2008) 19:1530-9. doi:10.1093/annonc/mdn292
43. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene (2005) 24:4660-71. doi:10.1038/sj.onc.1208561
44. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 7:96. doi:10.1186/1471-2164-7-96
45. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 69:4116-24. doi:10.1158/0008-5472.CAN-08-3441
46. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol (2010) 11:174-83. doi:10.1016/S1470-2045(09)70262-1
47. Goodson WH III, Moore DH II, Ljung BM, Chew K, Mayall B, Smith HS, et al. The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67. Breast Cancer Res Treat (2000) 59:113-23. doi:10.1023/A:1006344010050
48. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in breast cancer working group. J Natl Cancer Inst (2011) 103:1656-64. doi:10.1093/jnci/djr393
49. Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics (2006) 7:278. doi:10.1186/1471-2164-7-278
50. Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MC, et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol (2006) 24:3039-47. doi:10.1200/JCO.2006.05.6564
51. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 351:2817-26. doi:10.1056/NEJMoa041588
52. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 27:1160-7. doi:10.1200/JCO.2008.18.1370
53. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2010) 11:55-65. doi:10.1016/S1470-2045(09)70314-6
54. Eiermann W, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K, et al. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann Oncol (2013) 24:618-24. doi:10.1093/annonc/mds512
55. Horn L, Pao W, Johnson DH. Neoplasms of the lung. 18th ed. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, editors. Harrison's Principles of Internal Medicine. New York, NY: McGraw-Hill (2012). p. 737-53.
56. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med (2013) 137:668-84. doi:10.5858/arpa.2012-0263-RA
57. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2004) 22:2184-91. doi:10.1200/JCO.2004.11.022
58. Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP, Westra WH. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res (2010) 16:610-9. doi:10.1158/1078-0432.CCR-09-2638
59. Ring BZ, Seitz RS, Beck RA, Shasteen WJ, Soltermann A, Arbogast S, et al. A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol (2009) 22:1032-43. doi:10.1038/modpathol.2009.60
60. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 363:1693-703. doi:10.1056/NEJMoa1006448
61. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer Version 3.2014. (2014). Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
62. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn (2013) 15:415-53. doi:10.1016/j.jmoldx.2013.03.001
63. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 19:619-25. doi:10.1038/nm.3175
64. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med (2009) 361:2449-60. doi:10.1056/NEJMra0804588
65. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 96:8681-6. doi:10.1073/pnas.96.15.8681
66. Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer (2014) 134:552-62. doi:10.1002/ijc.28387
67. Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi Z, et al. Proteogenomic characterization of human colon and rectal cancer. Nature (2014) 513:382-7. doi:10.1038/nature13438
68. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2005) 92:131-9. doi:10.1038/sj.bjc.6602258
69. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Colon Cancer Version 1.2012. (2012). Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
70. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature (2012) 490:61-70. doi:10.1038/nature11412
71. Gerdes MJ, Sevinsky CJ, Sood A, Adak S, Bello MO, Bordwell A, et al. Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci U S A (2013) 110:11982-7. doi:10.1073/pnas.1300136110
72. Huang W, Hennrick K, Drew S. A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays. Hum Pathol (2013) 44:29-38. doi:10.1016/j.humpath.2012.05.009
73. Gallagher RI, Espina V. Reverse phase protein arrays: mapping the path towards personalized medicine. Mol Diagn Ther (2014) 18:619-30. doi:10.1007/s40291-014-0122-3
74. Kim P, Liu X, Lee T, Liu L, Barham R, Kirkland R, et al. Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients. Proteome Sci (2011) 9:75. doi:10.1186/1477-5956-9-75
75. Lee J, Kim S, Kim P, Liu X, Lee T, Kim KM, et al. A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers. PLoS One (2013) 8:e54644. doi:10.1371/journal.pone.0054644
76. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 285:1182-6. doi:10.1056/NEJM197111182852108
77. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature (2013) 501:346-54. doi:10.1038/nature12626
78. Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell (2010) 18:884-901. doi:10.1016/j.devcel.2010.05.012
79. Butcher DT, Alliston T, Weaver VM. A tense situation: forcing tumour progression. Nat Rev Cancer (2009) 9:108-22. doi:10.1038/nrc2544
80. Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech (2011) 4:165-78. doi:10.1242/dmm.004077
81. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell (2009) 139:891-906. doi:10.1016/j.cell.2009.10.027
82. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res (2012) 18:4266-76. doi:10.1158/1078-0432.CCR-11-3114
83. Roh-Johnson M, Bravo-Cordero JJ, Patsialou A, Sharma VP, Guo P, Liu H, et al. Macrophage contact induces RhoA GTPase signaling to trigger tumor cell intravasation. Oncogene (2014) 33:4203-12. doi:10.1038/onc.2013.377
84. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer (2004) 4:839-49. doi:10.1038/nrc1477
85. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer (2010) 10:505-14. doi:10.1038/nrc2868
86. Gordon MS, Mendelson DS, Kato G. Tumor angiogenesis and novel antiangiogenic strategies. Int J Cancer (2010) 126:1777-87. doi:10.1002/ijc.25026
87. Gray R, Giantonio BJ, O'Dwyer PJ, Sandler A, Miller K, Comis RL. The safety of adding angiogenesis inhibition into treatment for colorectal, breast, and lung cancer: the Eastern Cooperative Oncology Group's (ECOG) experience with bevacizumab (anti-VEGF). Proc Am Soc Clin Oncol (2003) 22:206: abstract 825.
88. Tewari KS, Sill MW, Long HJ III, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med (2014) 370:734-43. doi:10.1056/NEJMoa1309748
89. Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res (2008) 659:15-30. doi:10.1016/j.mrrev.2008.03.002
90. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature (2008) 454:436-44. doi:10.1038/nature07205
91. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res (2006) 66:605-12. doi:10.1158/0008-5472.CAN-05-4005
92. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer (2008) 8:618-31. doi:10.1038/nrc2444
93. Siveen KS, Kuttan G. Role of macrophages in tumour progression. Immunol Lett (2009) 123:97-102. doi:10.1016/j.imlet.2009.02.011
94. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell (2006) 124:263-6. doi:10.1016/j.cell.2006.01.007
95. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 16:91-102. doi:10.1016/j.ccr.2009.06.018
96. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, et al. IL-23 promotes tumour incidence and growth. Nature (2006) 442:461-5. doi:10.1038/nature04808
97. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 1:54-67. doi:10.1158/2159-8274.CD-10-0028
98. Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res (2012) 72:2162-71. doi:10.1158/0008-5472.CAN-11-3687
99. Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC, et al. Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol (2013) 20:946-55. doi:10.1245/s10434-012-2668-9
100. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (1996) 77:1303-10. doi:10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5
101. Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol (2007) 25:869-75. doi:10.1200/JCO.2006.08.9755
102. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell (2009) 16:183-94. doi:10.1016/j.ccr.2009.06.017
103. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res (2013) 19:5300-9. doi:10.1158/1078-0432.CCR-13-0143
104. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 363:411-22. doi:10.1056/NEJMoa1001294
105. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer Version 2.2014. (2014). Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
106. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 5:177-38. doi:10.1126/scitranslmed.3005930
107. Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 10:1. doi:10.1186/1479-5876-10-1
108. Hollman-Hewgley D, Lazare M, Bordwell A, Zebadua E, Triphathi P, Ross AS, et al. A single slide multiplex assay for the evaluation of classical Hodgkin lymphoma. Am J Surg Pathol (2014) 38:1193-202. doi:10.1097/PAS.0000000000000242
109. Schubert W, Bonnekoh B, Pommer AJ, Philipsen L, Böckelmann R, Malykh Y, et al. Analyzing proteome topology and function by automated multidimensional fluorescence microscopy. Nat Biotechnol (2006) 24:1270-8. doi:10.1038/nbt1250
110. Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A (2003) 55:61-70. doi:10.1002/cyto.a.10072
111. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud Ø, Giertsen BT, et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell (2004) 118:217-28. doi:10.1016/j.cell.2004.06.028
112. Chattopadhyay PK, Perfetto SP, Roederer M. The colorful future of cell analysis by flow cytometry. Discov Med (2004) 4:255-62.
113. Ledford H. The death of microarrays? Nature (2008) 455:847. doi:10.1038/455847a
114. Tripathy D, Harnden K, Blackwell K, Robson M. Next generation sequencing and tumor mutation profiling: are we ready for routine use in the clinic? BMC Med (2014) 12:140. doi:10.1186/s12916-014-0140-3
115. Hadd AG, Houghton J, Choudhary A, Sah S, Chen L, Marko AC, et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagn (2013) 15:234-47. doi:10.1016/j.jmoldx.2012.11.006
116. Spencer DH, Sehn JK, Abel HJ, Watson MA, Pfeifer JD, Duncavage EJ. Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens. J Mol Diagn (2013) 15:623-33. doi:10.1016/j.jmoldx.2013.05.004
117. Evers DL, He J, Kim YH, Mason JT, O'Leary TJ. Paraffin embedding contributes to RNA aggregation, reduced RNA yield, and low RNA quality. J Mol Diagn (2011) 13:687-94. doi:10.1016/j.jmoldx.2011.06.007
118. Walter RF, Mairinger FD, Wohlschlaeger J, Worm K, Ting S, Vollbrecht C, et al. FFPE tissue as a feasible source for gene expression analysis-a comparison of three reference genes and one tumor marker. Pathol Res Pract (2013) 209:784-9. doi:10.1016/j.prp.2013.09.007
119. Mittempergher L, de Ronde JJ, Nieuwland M, Kerkhoven RM, Simon I, Rutgers EJ, et al. Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue. PLoS One (2011) 6:e17163. doi:10.1371/journal.pone.0017163
120. Ibusuki M, Fu P, Yamamoto S, Fujiwara S, Yamamoto Y, Honda Y, et al. Establishment of a standardized gene-expression analysis system using formalin-fixed, paraffin-embedded, breast cancer specimens. Breast Cancer (2013) 20:159-66. doi:10.1007/s12282-011-0318-x
121. Xiao JF, Zhou B, Ressom HW. Metabolite identification and quantitation in LC-MS/MS-based metabolomics. Trends Analyt Chem (2012) 32:1-14. doi:10.1016/j.trac.2011.08.009
122. Brown MV, McDunn JE, Gunst PR, Smith EM, Milburn MV, Troyer DA, et al. Cancer detection and biopsy classification using concurrent histopathological and metabolomic analysis of core biopsies. Genome Med (2012) 4:33. doi:10.1186/gm332
123. Kortz L, Dorow J, Ceglarek U. Liquid chromatography-tandem mass spectrometry for the analysis of eicosanoids and related lipids in human biological matrices: a review. J Chromatogr B Analyt Technol Biomed Life Sci (2014) 964:1-11. doi:10.1016/j.jchromb.2014.01.046
124. Wisiewski JR, Ostasiewicz P, Dus K, Zielinska DF, Gnad F, Mann M. Extensive quantitative remodelling of the proteome between normal colon tissue and adenocarcinoma. Mol Syst Biol (2012) 8:1-14. doi:10.1038/msb.2012.44
125. Chaurand P. Imaging mass spectrometry of thin tissue sections: a decade of collective efforts. J Proteomics (2012) 75:4883-92. doi:10.1016/j.jprot.2012.04.005
126. Bandura DR, Baranov VI, Ornatsky OI, Antonov A, Kinach R, Lou X, et al. Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal Chem (2009) 81:6813-22. doi:10.1021/ac901049w
127. Wang HA, Grolimund D, Giesen C, Borca CN, Shaw-Stewart JR, Bodenmiller B, et al. Fast chemical imaging at high spatial resolution by laser ablation inductively coupled plasma mass spectrometry. Anal Chem (2013) 85:10107-16. doi:10.1021/ac400996x
128. Giesen C, Wang HA, Schapiro D, Zivanovic N, Jacobs A, Hattendorf B, et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods (2014) 11:417-22. doi:10.1038/nmeth.2869
129. Angelo M, Bendall SC, Finck R, Hale MB, Hitzman C, Borowsky AD, et al. Multiplexed ion beam imaging of human breast tumors. Nat Med (2014) 20:436-42. doi:10.1038/nm.3488